MedPath
HSA Product

Telfast Oral Suspension 6 mg/ml

Product approved by Health Sciences Authority (SG)

Basic Information

Telfast Oral Suspension 6 mg/ml

SUSPENSION

Regulatory Information

SIN14199P

July 20, 2012

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XR06AX26

Company Information

OPELLA HEALTHCARE SINGAPORE PTE. LTD.

OPELLA HEALTHCARE SINGAPORE PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**CONTRAINDICATIONS** TELFAST oral suspension is contraindicated in patients with known hypersensitivity to fexofenadine and any of the ingredients of TELFAST. Rare cases of hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported.

Indication Information

**INDICATIONS AND USAGE** - **Seasonal Allergic Rhinitis** TELFAST is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older. - **Chronic Idiopathic Urticaria** TELFAST is indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.

© Copyright 2025. All Rights Reserved by MedPath